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Abstract 
Chemotherapy-induced nausea and vomiting (CINV) is a major adverse event associated with cancer treatments. There are clinical 
practice guidelines that assist practitioners in managing CINV.  Many cancer centers develop protocols for physicians and 
pharmacists to guide prophylaxis and breakthrough treatments of CINV based on published guidelines.  The purpose of this study was 
to evaluate the outcome differences between pharmacist and physician -driven management of CINV in adult hospitalized cancer 
patients in a large academic medical center.  This is a single center retrospective chart review study.  The primary outcome of the 
study was the number of breakthrough antiemetic doses needed throughout the hospitalization.  A total of 106 adult patients 
receiving inpatient chemotherapy were reviewed for CINV management.  Fifty-five patients (52%) were managed according to the 
pharmacist-driven protocol, and fifty-one patients (48%) were managed by the physician.  There was no difference between the two 
groups in the primary outcome.  Patients in the pharmacist-managed group needed 6.4 breakthrough antiemetic doses; whereas, 
patients in the physician managed group needed 5.9 doses throughout the hospital stay (P-value = 0.7).  No difference was seen 
when results were adjusted for length of hospitalization.  There was a difference in adherence to the institution CINV guidelines 
favoring the pharmacist-driven approach (85% versus 33%, P < 0.0001).  In conclusion, pharmacist-run protocol for CINV 
management was as effective as the standard of care.  Protocols that are based on practice guidelines may offer the advantage of 
care standardization and potential cost savings. 
 
 
Introduction 
Chemotherapy-induced nausea and vomiting (CINV) is a 
major adverse event associated with cancer treatments.  
CINV significantly affects a patient’s quality of life, and the 
severity of episodes may also affect their compliance and the 
intended treatment intensity.
1
 It is considered one of the 
most distressing and feared adverse effects experienced by 
patients receiving chemotherapeutic or radiation 
treatments.
2,3
  There are clinical practice guidelines that assist 
the effective management of CINV symptoms by oncology 
practitioners.
4,5,6
  Guidelines aim to prevent CINV from 
developing following the administration of chemotherapy or 
radiation treatments.  CINV is classified into five distinct 
categories: acute, delayed, anticipatory, refractory and 
breakthrough nausea and vomiting.
4,5,6
  The type and 
intensity of chemotherapy or radiation treatments affect the 
severity of CINV episodes and therefore, the recommended 
treatment regimens.  Some patient specific risk factors 
contribute to the incidence and intensity of CINV.  Risk factors 
in the acute phase include female sex, younger age, history of 
refractory CINV, history of motion sickness, anxiety and 
absence of alcohol use.
4,7 
 Risk factors in the delayed phase 
include female sex and poor control in the acute phase.
4,7
  
Clinical practice guidelines classify chemotherapeutic agents 
based on the incidence of emesis.  They are classified into 
high (incidence >90%), moderate (30-90%), low (10-30%) and 
minimal (<10%).
4,5,6  
 
 
Despite the recent advances in antiemetic agents, including 
the introduction of 5-HT3 antagonists starting in the 1990s 
and Neurokinin-1 (NK1) antagonists in 2006, patients 
continue to struggle with CINV.
7
 Recent studies suggest that 
an element of the continued struggle with CINV can be the 
failure of health care providers to adequately anticipate its 
incidence, understand its complex physiology and adhere to 
recommended guidelines.
7,8 
  
 
Clinical practice guidelines provide agent and dosage 
recommendations, but agent of choice and dosing algorithm 
may differ among cancer centers and oncology practitioners.
9
 
Cancer centers develop institution-specific protocols for CINV 
prophylaxis and breakthrough treatments that are based on 
published practice guidelines. These guidelines assist 
practitioners and house staff in decision making.  Many 
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institutions also develop pharmacist-driven protocols 
approved by the Pharmacy &Therapeutics Committee for the 
prophylaxis and breakthrough treatments of CINV.  Such 
protocols allow clinical pharmacists to provide appropriate 
antiemetic regimens based on chemotherapy administered 
and other patient specific factors.  They also allow clinical 
pharmacists to provide regimens for breakthrough symptoms 
without the prior authorization of the prescribing oncologist.  
This not only provides a tool to standardize treatment 
strategies across the institution, but also saves needed time 
when patients are experiencing breakthrough episodes.  The 
use of such protocols remains voluntary, and oncologists can 
prescribe antiemetic regimen based on their clinical 
judgment. 
  
The purpose of this study was to evaluate the clinical 
outcome differences between pharmacist and physician-
driven management of CINV in adult cancer patients in a large 
academic medical center. 
 
Methods 
Study design and patient population 
This is a single center retrospective chart review study.  The 
Investigational Review Board of the academic medical center 
approved the study protocol.  Medical records of patients 
admitted to the Medical Hematology/Oncology unit for 
scheduled inpatient chemotherapy between February 2010 
and August 2010 were reviewed.  Inclusion criteria included 
age over 18 years, confirmed cancer diagnosis and active 
inpatient chemotherapy during the hospitalization.  Patients 
with confirmed cancer diagnosis were defined as those with a 
documented new or recurrent cancer diagnosis at time of 
hospital admission including solid organ tumors, leukemia 
and lymphoma.  Exclusion criteria included surgical patients, 
non-cancer diagnoses and those admitted for chemotherapy 
desensitization. 
 
Data Collection 
Data was extracted from patients’ electronic medical records 
by the study principal investigator.  Data collected included 
general characteristics of patients such as demographic data, 
diagnosis and clinical course throughout the hospital stay.  
Chemotherapy admission orders were reviewed to determine 
whether the patient’s antiemetic regimen was managed by 
the prescribing oncologist or the pharmacist-managed 
protocol. Electronic medication administration records were 
reviewed by the investigator to determine the number of 
breakthrough doses needed during the hospital stay,.  
Breakthrough doses were defined as all doses needed for 
breakthrough nausea and vomiting and did not include any 
scheduled prophylaxis antiemetic doses. 
 
Outcome Assessments 
The primary outcome of the study was the number of 
breakthrough antiemetic doses needed throughout the 
hospital stay as a surrogate marker of the quality of CINV 
management.  Secondary outcomes included the rate of 
adherence to the institution protocol which is largely based 
on the nationally and internationally recognized clinical 
practice guidelines.
4,5,12  
Patients’ chemotherapy and 
antiemetic regimens were compared against the institution 
CINV protocol by the study investigator to determine the 
appropriateness of prophylaxis and breakthrough regimens 
prescribed at the time of admission.  Adherence to the 
institution protocol was defined as prescribing prophylaxis 
and breakthrough regimens that are in accordance with the 
institution CINV protocol.  Inappropriate regimens were 
defined as those lacking one or more antiemetic agents.  
Excessive prophylaxis regimens were defined as those 
providing more antiemetic doses than recommended by the 
institution CINV guidelines.  The antiemetic agent, its 
frequency and the total number of doses used were 
evaluated to determine the appropriateness of the regimen.  
However, the dose of antiemetic agents was not used in the 
review criteria.  Secondary outcomes also included the total 
number of breakthrough doses and number of doses per 
hospital day stratified according to chemotherapy regimen 
and its corresponding risk of CINV. 
 
Statistical Analysis 
The mean or median was calculated for continuous variables 
such as age, number of doses and number of doses per 
hospital day.  We used the Student t-test or the Wilcoxon 
rank sum test to assess differences in the means or medians, 
respectively.  Categorical variables-such as gender, 
appropriateness of regimen and rate of adherence-were 
compared using the X
2
 test or Fisher exact test.  All tests were 
two-tailed, and a p-value of < 0.05 was considered to be 
statistically significant.  A sample size of 86 (43 per group) 
was calculated prospectively to yield a statistical power of 
80% to detect a difference of five breakthrough antiemetic 
doses needed throughout the hospital stay. 
 
Results 
Patients 
A total of 110 patient charts were reviewed.  Four charts did 
not meet the inclusion criteria.  The remaining 106 charts met 
the inclusion criteria and were reviewed.  Fifty-five patients 
(52%) were managed according to the pharmacist-managed 
protocol, and fifty-one patients (48%) were managed by the 
prescribing oncologist and the house medical staff.  Overall, 
there were more male than female patients (65% versus 35%, 
P = 0.003).  The most common diagnosis was lymphoma (40% 
of all patients), followed by sarcoma (21%) then leukemia 
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(17%).  Most patients in the pharmacist-managed group (54 
of 55, 98%) were diagnosed with either leukemia or 
lymphoma.  The most common diagnosis in the physician-
managed group was sarcoma (43%) followed by ovarian 
cancer (18%).  The median age of all patients was 51 (range 
18-87).  Summary of demographics and diagnoses on 
admission is shown in Table 1.  Most chemotherapy regimens 
used were those with moderate to high emetic risk with high 
risk for delayed CINV.  Chemotherapy regimens with 
moderate emetic risk were the most common in the 
pharmacist-managed group (40% of all regimens), followed 
by regimens with high emetic risk with high risk for delayed 
effects (31%).  Regimens with moderate emetic risk with high 
risk for delayed CINV were the most common in the 
physician-managed group (37% of all regimens), followed by 
regimens with moderate emetic risk (27%).  (Table 2) 
 
Primary End Point 
There was no statistically significant difference between the 
two study groups in the primary outcome.  Patients managed 
according to the pharmacist protocol needed an average of 
6.4 breakthrough antiemetic doses throughout the hospital 
stay; whereas, patients managed by the prescribing 
oncologist or the house medical staff needed an average of 
5.9 doses throughout the hospital stay (P = 0.7).  Length of 
hospital stay was similar between the two study groups, 7.6 
days in the pharmacist-managed group and 5.6 days in the 
physician-managed group (P = 0.07) (Table 1).  Adjustment 
for length of hospital stay was performed.  Patients in the 
pharmacist managed group needed an average of 0.85 
breakthrough doses per day of hospitalization; whereas, 
patients managed by the oncologist or house medical staff 
needed an average of 0.91 breakthrough doses per day of 
hospitalization (P = 0.78).  
 
Secondary End Points 
There was a statistically significant difference in the rate of 
adherence to the institution guidelines.  In the pharmacist-
managed group, the rate of adherence was 85% (47 out of 55 
cases), while in the physician managed group the rate of 
adherence was 33% (17 out of 51 cases) (P < 0.0001). (Table 
3)  The most common reason for non-adherence in the 
physician-managed group was the lack of appropriate 
coverage for delayed CINV.  In the physician managed group, 
22 of 34 non-adherence cases (65%) were due to 
inappropriate delayed CINV antiemetic regimen, 10 of 34 
non-adherence cases (29%) were due to excessive 
prophylaxis regimen, 1 case (3%) was due to inappropriate 
prophylaxis regimen and 1 case (3%) was due to lack of 
breakthrough regimen.  In the pharmacist-managed group, 7 
of 8 non-adherence cases (87%) lacked appropriate delayed 
CINV antiemetic regimen and 1 case (13%) was due to 
excessive prophylaxis regimen (Figure 1).  Data was stratified 
into five distinct categories according to CINV risk associated 
with chemotherapy regimen used.  There was no statistically 
significant difference in outcomes in all categories except 
one.  In chemotherapy regimens with high emetic risk with 
high risk for delayed CINV, there was a difference favoring the 
physician-managed group (0.65 versus 1.1 breakthrough 
doses per day of hospitalization; P = 0.05).  There was no 
difference in all the other groups (Table 4). 
 
Discussion 
In this retrospective chart review study, there was no 
statistically significant difference between the two study 
groups in the total number of breakthrough doses needed for 
CINV: 6.4 doses per encounter in the pharmacist managed 
group compared to 5.9 in the physician managed group (P = 
0.7).  There was also no significant difference when results 
were adjusted for length of hospital stay (0.85 doses per day 
versus 0.91, P = 0.78).  There was a significant difference in 
the rate of adherence to the institution protocol favoring the 
pharmacist-managed approach (85% versus 33%, P < 0.0001).  
When data was stratified according to CINV risk associated 
with chemotherapy regimens used, there was a difference 
favoring the physician-managed group for regimens with high 
CINV risk with high risk for delayed symptoms. 
  
In the physician-managed group, 20% of patients (10 of 51 
cases) received excessive CINV prophylaxis regimens 
compared to only 2% in the pharmacist-managed group (1 of 
55 cases).  Four of eleven patients who received 
chemotherapy regimens with high emetic risk with high risk 
for delayed CINV, and who were managed by the physician, 
had excessive antiemetic prophylaxis regimens.  Excessive 
prophylaxis regimens generally included scheduled 
ondansetron, dosed three to four times per day throughout 
the hospital course regardless of the chemotherapy schedule.  
However, it is unclear if this pattern of excessive prophylaxis 
regimens can explain the difference seen in this subgroup.  
This observation suggests that over prescribing prophylactic 
antiemetic regimens may not correlate with less 
breakthrough CINV episodes.  This also presents an 
economical aspect and an area of potential cost savings. 
  
To our knowledge, this is the first study that directly 
compares the two management approaches.  Several studies 
had demonstrated the added value when clinical pharmacists 
were directly involved in cancer patients’ care as the drug 
experts.
10,11
  The results of this study are consistent with that 
notion.  The need for the pharmacist involvement grew 
significantly with the shift from a disease-centered to a 
patient-centered care.
10
 With that shift, patient’s quality of 
life became a measure that is, perhaps, as important as the 
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disease progression.
11
 Areas in cancer supportive care where 
pharmacists contribute to patient care and quality of life 
includes pain management, anemia, co-morbid conditions 
and chemotherapy or radiation induced nausea and vomiting. 
  
The interpretation of the results of this study is limited by the 
retrospective nature of the study design.  Patients in the two 
study groups were not well matched with regard to gender 
and admission diagnosis.  Other variables that may have 
affected the outcomes of the study, but could not be studied 
due to limited data, include severity of disease, CINV risk 
factors, co-morbid conditions and history of radiation 
treatments.   
  
Clinical Practice Guidelines are defined as systemically 
developed statements, for specific clinical circumstances, that 
assist practitioner and patient decisions about appropriate 
health care.
13 
Given the evidence-based nature of clinical 
practice guidelines, it is essential to adhere to their 
recommendations especially when clinical outcomes are tied 
to clearly defined measures such as mortality or cure rates.  
The implementation of such guidelines can be difficult in the 
area of supportive care due to its subjective nature and the 
lack of clearly defined outcomes like mortality or cure rates.  
In such case, one can argue that guidelines for CINV 
management should serve as an educational tool to improve 
practitioners’ understanding of chemotherapy- induced 
nausea and vomiting and its effective management.  Kaiser 
and colleagues argue that better adherence to antiemetic 
guidelines can only be achieved through a complex and long-
term process, consisting of efficient education, training, and 
monitoring of all individuals involved.
14
 The purpose of this 
study was not to advocate for the strict adherence to 
nationally recognized guidelines for CINV management.  
Indeed, there are some patient specific factors that can drive 
the clinical decision away from suggested treatments such as 
history of adverse reactions or existence of co-morbid 
conditions.  When such factors are not contributing to the 
decision making process, the argument for following the 
suggested treatments is much stronger. 
  
In conclusion, pharmacist-managed protocol for the clinical 
management of CINV was as effective as the standard of care.  
Pharmacist-managed protocols that are based on nationally 
recognized practice guidelines might offer the advantage of 
standardization of care and potential cost savings. 
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Table-1. Demographic Characteristics of Patients 
Characteristic  
Pharmacist 
managed Group             
(N=55) 
Physician 
Managed 
Group (N=51) 
All Patients 
(N=106) 
P-Value 
Gender, n (%)      
 Male 41 (75) 28 (55) 69 (65) 0.003 
 Female 14 (25) 23 (45) 37 (35) 0.003 
      
Age, Years
1
  47±16 52±14 49±15 0.12 
      
Diagnosis, n (%)       
 Leukemia 16 (29) 2 (4) 18 (17)  
 Lymphoma 38 (69) 5 (10) 43 (40)  
 Sarcoma 0 (0) 22 (43) 22 (21)  
 Ovarian Cancer 0 (0) 9 (18) 9 (8)  
 Testicular Cancer 0 (0) 1 (2) 1 (1)  
 Renal Cell Carcinoma 0 (0) 2 (4) 2 (2)  
 Small Cell Lung Carcinoma 1 (2) 1 (2) 2 (2)  
 Head and Neck Cancer 0 (0) 3 (6) 3 (3)  
 Other 0 (0) 6 (12) 6 (6)  
      
LOS, Days
1,2
  7.6±5.7 5.6±3.6 6.7±5 0.03 
 
1) Plus–minus values are means ±SD 
2) LOS: Length of Stay 
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Table-2. Emetogenecity of Chemotherapy Regimens Used 
Emetic Risk
#
 
Pharmacist managed 
Group 
N=55 
n (%) 
Physician Managed 
Group 
N=51 
n (%) 
All Patients 
N=106 
n (%) 
P-value 
HEC 0 (0) 0 (0) 0 (0) -- 
HEC+D 17 (31) 11 (22) 28 (26) 0.15 
MEC 22 (40) 14 (27) 36 (34) 0.05 
MEC+D 13 (24) 19 (37) 32 (30) 0.05 
LEC 1 (1.5) 4 (8) 5 (5) 0.03 
Minimal 2 (3.5) 3 (6) 5 (5) 0.4 
 
 HEC: High Emetogenic Chemotherapy 
HEC+D: High Emetogenic Chemotherapy with High Risk of Delayed Nausea and Vomiting 
 MEC: Moderate Emetogenic Chemotherapy 
MEC+D: Moderate Emetogenic Chemotherapy with High Risk of Delayed Nausea and Vomiting 
 LEC: Low Emetogenic Chemotherapy 
 Minimal: Minimal Emetogenic Chemotherapy 
 
#
 Risk according to nationally recognized practice guidelines.
4,5,6 
 
 
 
 
 
 
Table-3. Rate of Adherence to The Institution Protocol and guidelines 
Adherence to 
Guidelines 
Pharmacist Managed 
Group 
 N= 55
*
 
Physician Managed 
Group 
N= 51
*
 
All Patients 
N= 106 
Yes, n (%) 47 (85) 17 (33) 64 (60) 
No, n (%) 8 (15) 34 (67) 42 (40) 
 
 1) P-value < 0.0001 favoring the pharmacist group for rate of adherence to the institution CINV protocol. 
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Table-4. Summary of Number of Breakthrough Doses Based on Chemotherapy Regimen Used 
Emetic Risk 
#
 
Pharmacist-
Managed Group 
Physician-
Managed Group 
All Patients P-Value 
HEC+D 
10 (1.1) 
n = 17 
3.5 (0.65) 
n = 11 
7.4 (0.9)  
n = 28 
0.05 
MEC 
6.5 (0.8) 
n = 22 
10.2 (1.6) 
n = 14 
7.9 (1.1) 
n = 36 
0.48 
MEC+D 
3.4 (0.8) 
n = 13 
5.3 (0.7) 
n = 19 
4.5 (0.7) 
n = 32 
0.37 
LEC 
0 (0) 
n = 1 
4.25 (0.7) 
n = 4 
3.4 (0.6) 
n = 5 
- 
Minimal 
0.5 (0.1) 
n = 2 
1.7 (0.5) 
n = 3 
1.2 (0.4) 
n = 5 
- 
 
1) Values are presented as average number of breakthrough doses per hospitalization (number of doses per day of hospitalization). 
All Patients column presents average values for all patients receiving chemotherapy with the respective risk category.  
 
2) HEC: High Emetogenic Chemotherapy 
HEC+D: High Emetogenic Chemotherapy with High Risk of Delayed Nausea and Vomiting 
MEC: Moderate Emetogenic Chemotherapy 
MEC+D: Moderate Emetogenic Chemotherapy with High Risk of Delayed Nausea and Vomiting 
LEC: Low Emetogenic Chemotherapy 
Minimal: Minimal Emetogenic Chemotherapy 
 
3) 
#
 Risk according to nationally recognized practice guidelines.
4,5,6 
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Figure 1. Reasons for Non-Adherence to The Institution Protocol and Guidelines 
 
Pharmacist Managed Group, N = 8 Non-Adherence Cases 
 
 
 
 
Physician Managed Group, N = 34 Non-Adherence Cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87% 
13% 
Inappropriate Delayed CINV 
Regiemn 
Excessive Prophylaxis 
Regimen 
65% 
3% 
29% 
3% 
Inappropriate Delayed CINV 
Regimen 
Inappropriate Prophylaxis 
Regimen 
Excessive Prophylaxis Regimen 
Lack of Breakthrough Regimen 
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Appendix A: Institutional Guidelines for the Management of CINV 
 
Highly Emetogenic Chemotherapy (HEC): 
 Ondansetron 12 mg PO or IV 30-60 minutes before each dose of HEC 
 Dexamethasone 12 mg PO or IV 30 to 60 minutes before each dose of HEC 
 Dexamethasone 8 mg PO daily x3 days (starting the day after the last day of HEC) 
 Aprepitant 125 mg PO x1 dose 30 to 60 minutes before chemo dose on day 1 
 Aprepitant 80 mg PO daily for 2 days (starting day 2) 
 
Moderately Emetogenic Chemotherapy with High Risk of Delayed CINV (Carboplatin, Cyclophosphamide, Doxorubicin, 
Epirubicin, Ifosfamide, Irinotecan, Methotrexate) (MEC+D): 
 Ondansetron 8 mg PO or IV 30-60 minutes before each dose of MEC+D 
 Dexamethasone 8 mg PO or IV 30 to 60 minutes before each dose of MEC+D 
 Dexamethasone 8 mg PO daily x3 days (starting the day after the last day of   MEC+D) 
 Aprepitant 125 mg PO x1 dose 30 to 60 minutes before chemo dose on day 1 
 Aprepitant 80 mg PO daily for 2 days (starting day 2) 
 
Moderately Emetogenic Chemotherapy (MEC): 
 Ondansetron 8 mg PO 30 to 60 minutes before each dose of MEC 
 Dexamethasone 8 mg PO 30-60 minutes before each dose of MEC 
 
Low Emetogenic Chemotherapy (LEC): 
 Prochlorperazine 10 mg PO 30-60 minutes before each dose of LEC 
 
PRN Antiemetic for Patients ≥65 years old: 
 Prochlorperazine 5-10 mg PO or IV every 6 hours as needed 
 Lorazepam 0.5-1 mg PO or IV every 6 hours as needed 
 
PRN Antiemetic for Patients <65 years old: 
 Prochlorperazine 10 mg PO or IV every 6 hours as needed 
 Lorazepam 0.5-1 mg PO or IV every 6 hours as needed 
 
 
 
